ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 698

Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus

Ilana Abeles1 and Vasileios Kyttaris 2, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biomarkers, SLE and interferons

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Gene expression studies have previously demonstrated increased Type I interferon α (IFN) inducible genes in peripheral blood mononuclear cells of systemic lupus erythematosus (SLE) patients as compared to controls. Prior studies also showed increased IFNα gene expression is associated with markers of disease activity, both by disease activity scores and serological markers (Kennedy et al, 2015 and Kirou et al 2005). Despite the success of large phase II trials of anti-IFN therapies in patients with SLE, phase III trials were reportedly negative. Identifying the optimal biomarker in order to target the appropriate population of SLE patients to receive anti-IFN therapy remains elusive and a critical goal. Rather than using IFNα inducible genes as biomarkers, we investigated IFNα subtype expression in SLE patients versus healthy controls. We also evaluated associations of IFNα subtype expression in SLE patients with disease-related characteristics and clinical phenotype.

Methods: Patients were recruited from Beth Israel Deaconess Medical Center and the protocol was approved by our institution’s IRB. We obtained serum samples from 26 patients and 4 controls. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) of interferon α subtypes (1, 2, 4, 5, 6, 7, 8, 10, 14, 16, 17, 21) and β-actin mRNA were done using the Inexsia/Amplikine platform (PBL InterferonSource, Piscataway, NJ).  For each mRNA/cDNA in the sample, the fluorescence threshold cycle (Ct) during the amplification reaction was identified. The Dct was then calculated for each interferon α subtype mRNA by subtracting its Ct from the β-actin Ct (Dct interferon α subtype=Ctactin-Ctinterferon α subtype).  Statistical analyses were done using SPSS. Between group differences were analyzed with independent samples t-test. Multiple linear regression analyses were conducted to evaluate for independent associations between IFNα expression, SLEDAI, autoantibodies, markers of disease activity and clinical phenotypes. Follow up correlational analyses were done using Pearson’s correlation.

Results: Analyses revealed that Type I IFN α2 mRNA expression in patients’ peripheral blood mononuclear cells was elevated as compared to controls (p = 0.02, t= -2.65). No other subtypes demonstrated between group differences. Type I IFN α2 mRNA expression in patients trended towards correlating with disease activity as measured by SLEDAI scores (p =0.07, F= 4.2). There was also a trend found for a correlation between IFN α2 expression and lupus nephritis (R=.48, p=.067). No serological markers of disease activity or autoantibodies were significantly associated with IFN α2 expression.

Conclusion: Prior studies and clinical trials investigating IFNα in SLE used surrogate markers to deduce IFNα production. We propose that direct measurement of IFNα production at the mRNA level is feasible and can potentially be used as a biomarker for guiding anti-IFNα therapy in patients with SLE.


Disclosure: I. Abeles, None; V. Kyttaris, exagen diagnostics, 2, Exagen Diagnostics, 2, GSK, 5, gsk, 5, horizon pharma, 5, Horizon Pharma, 5.

To cite this abstract in AMA style:

Abeles I, Kyttaris V. Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/measurement-of-type-i-ifn%ce%b1-production-at-the-mrna-level-and-its-potential-use-as-a-biomarker-in-systemic-lupus-erythematosus/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/measurement-of-type-i-ifn%ce%b1-production-at-the-mrna-level-and-its-potential-use-as-a-biomarker-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences